Header Logo

Connection

KEITH A BAGGERLY to Drug Monitoring

Back to Details
This is a "connection" page, showing publications KEITH A BAGGERLY has written about Drug Monitoring.
KEITH A BAGGERLY
Connection Strength
0.027
Drug Monitoring
  1. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.